Evidence map›Paper›PMID 27095138›Full record

ArticleStem cells (Dayton, Ohio)2016

Loss of Folliculin Disrupts Hematopoietic Stem Cell Quiescence and Homeostasis Resulting in Bone Marrow Failure.

Masaya Baba, Hirofumi Toyama, Lei Sun, Keiyo Takubo, Hyung-Chan Suh, Hisashi Hasumi, Ayako Nakamura-Ishizu, Yukiko Hasumi, Kimberly D Klarmann, Naomi Nakagata and 4 more

Open access · hybridAbstract read
In one paragraph

Article in Stem cells (Dayton, Ohio), 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
1.9field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 32 citations in OpenAlex.

  1. Article
  2. Current oncology (Toronto, Ont.) · 2025
    Article
  3. Review
  4. Review
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Folliculin Regulates Osteoclastogenesis Through Metabolic Regulation.Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research · 2018
    Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 6 institutions in 3 countries.

Masaya BabaUrologic Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
Hirofumi ToyamaDepartment of Cell Differentiation, The Sakaguchi Laboratory of Developmental Biology, School of Medicine, Keio University, 35 Shinano-machi, Shinjuku-ku, Tokyo, Japan.
Lei SunMouse Cancer Genetics Program, Frederick, Maryland, USA.
Keiyo TakuboDepartment of Cell Differentiation, The Sakaguchi Laboratory of Developmental Biology, School of Medicine, Keio University, 35 Shinano-machi, Shinjuku-ku, Tokyo, Japan.
Hyung-Chan SuhMouse Cancer Genetics Program, Frederick, Maryland, USA.
Hisashi HasumiUrologic Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
Ayako Nakamura-IshizuDepartment of Cell Differentiation, The Sakaguchi Laboratory of Developmental Biology, School of Medicine, Keio University, 35 Shinano-machi, Shinjuku-ku, Tokyo, Japan.
Yukiko HasumiUrologic Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
Kimberly D KlarmannMouse Cancer Genetics Program, Frederick, Maryland, USA.
Naomi NakagataDivision of Reproductive Engineering, Center for Animal Resources and Development (CARD), Kumamoto University, Kumamoto, Japan.
Laura S SchmidtUrologic Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
W Marston LinehanUrologic Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
Toshio SudaInternational Research Center for Medical Sciences (IRCMS), Kumamoto University, Kumamoto, Japan.
Jonathan R KellerMouse Cancer Genetics Program, Frederick, Maryland, USA.
Center for Cancer Research · USLeidos (United States) · USKeio University · JPNational Cancer Institute · USNational University of Singapore · SGKumamoto University · JP

Funding

Molecular Therapeutics of Kidney Cancer: MET Gene and BHD GeneZIABC011043 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI LINEHAN, WILLIAM MARSTON · 2009 to 2025
$20.9M
Clinical Studies of the Molecular Genetic Basis of Kidney CancerZIABC011028 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI LINEHAN, WILLIAM MARSTON · 2009 to 2025
$17.9M
Molecular-Cellular Regulation of Hematopoietic Stem CellsZIABC010001 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI KELLER, JONATHAN R · 2009 to 2024
$16.8M
Regulation of Hematopoiesis: Gene Therapy PotentialZ01BC010001 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI KELLER, JONATHAN R · 1996 to 2008
$2.1M
CCR NIH HHS HHSN261200800001CIntramural NIH HHS Z01 BC010001NCI NIH HHS HHSN261200800001E
6 · The paper itself

Abstract

Folliculin (FLCN) is an autosomal dominant tumor suppressor gene that modulates diverse signaling pathways required for growth, proliferation, metabolism, survival, motility, and adhesion. FLCN is an essential protein required for murine embryonic development, embryonic stem cell (ESC) commitment, and Drosophila germline stem cell maintenance, suggesting that Flcn may be required for adult stem cell homeostasis. Conditional inactivation of Flcn in adult hematopoietic stem/progenitor cells (HSPCs) drives hematopoietic stem cells (HSC) into proliferative exhaustion resulting in the rapid depletion of HSPC, loss of all hematopoietic cell lineages, acute bone marrow (BM) failure, and mortality after 40 days. HSC that lack Flcn fail to reconstitute the hematopoietic compartment in recipient mice, demonstrating a cell-autonomous requirement for Flcn in HSC maintenance. BM cells showed increased phosphorylation of Akt and mTorc1, and extramedullary hematopoiesis was significantly reduced by treating mice with rapamycin in vivo, suggesting that the mTorc1 pathway was activated by loss of Flcn expression in hematopoietic cells in vivo. Tfe3 was activated and preferentially localized to the nucleus of Flcn knockout (KO) HSPCs. Tfe3 overexpression in HSPCs impaired long-term hematopoietic reconstitution in vivo, recapitulating the Flcn KO phenotype, and supporting the notion that abnormal activation of Tfe3 contributes to the Flcn KO phenotype. Flcn KO mice develop an acute histiocytic hyperplasia in multiple organs, suggesting a novel function for Flcn in macrophage development. Thus, Flcn is intrinsically required to maintain adult HSC quiescence and homeostasis, and Flcn loss leads to BM failure and mortality in mice.

Indexed as

AnimalsBasic Helix-Loop-Helix Leucine Zipper Transcription FactorsBone Marrow CellsCell DifferentiationCell LineageCell ProliferationEmbryonic DevelopmentEstroneHematopoietic Stem CellsHomeostasisMacrophagesMiceMice, KnockoutBasic Helix-Loop-Helix Leucine Zipper Transcription FactorsEstroneTcfe3 protein, mouseBone marrow failureFolliculinHematopoiesisStem cells

Identifiers

PMID27095138
PMCPMC4843833
OpenAlexW2270283872

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.